Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00035841 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of TLK286 in Metastatic Breast Cancer

A Phase 2 study of Breast Neoplasms, sponsored by Telik.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
3
Study locations

NCT00035841 is a Phase 2 study of Breast Neoplasms that has completed, run by Telik. The registered enrollment target is 60 participants, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00035841, a Phase 2 study of Breast Neoplasms, has completed, sponsored by Telik.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.

Conditions Studied

Breast Neoplasms

Interventions

  • DRUG TLK286

Study Locations (3)

Arizona

  • Arizona Cancer Center - Tucson

Indiana

  • Indiana University Medical Center - Indianapolis

Ohio

  • Cleveland Clinic Taussig Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2002-04
Est. Completion 2004-07
Phase Phase 2

Sponsor

Telik

21 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00035841

The ClinicalTrials.gov registry entry for NCT00035841 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (89% lower). The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which TLK286 is the first listed.

NCT00035841 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Indiana, Ohio.

Frequently Asked Questions

What is clinical trial NCT00035841 about?

NCT00035841 is a clinical study titled "Phase 2 Study of TLK286 in Metastatic Breast Cancer". The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.

What is the current status of trial NCT00035841?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2002-04. Estimated completion is 2004-07.

What conditions does trial NCT00035841 study?

This clinical trial studies the following conditions: Breast Neoplasms.

What interventions are being tested in trial NCT00035841?

The interventions under investigation include: TLK286 (DRUG).

Who is sponsoring clinical trial NCT00035841?

This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00035841 being conducted?

This trial has 3 study locations across Arizona, Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Neoplasms

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.